Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Receivables (2021 - 2025)

Pulse Biosciences has reported Receivables over the past 3 years, most recently at $15000.0 for Q3 2025.

  • Quarterly results put Receivables at $15000.0 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $15000.0 (changed N/A YoY), and the annual figure for FY2021 was $61000.0, changed.
  • Receivables for Q3 2025 was $15000.0 at Pulse Biosciences, up from $5000.0 in the prior quarter.
  • Over the last five years, Receivables for PLSE hit a ceiling of $72000.0 in Q3 2021 and a floor of $5000.0 in Q3 2022.
  • Median Receivables over the past 3 years was $18000.0 (2022), compared with a mean of $30333.3.
  • Peak annual rise in Receivables hit 93.06% in 2022, while the deepest fall reached 93.06% in 2022.
  • Pulse Biosciences' Receivables stood at $61000.0 in 2021, then crashed by 91.8% to $5000.0 in 2022, then skyrocketed by 200.0% to $15000.0 in 2025.
  • The last three reported values for Receivables were $15000.0 (Q3 2025), $5000.0 (Q3 2022), and $8000.0 (Q2 2022) per Business Quant data.